Danaher Corporation · NYSE:DHR
Danaher — Q4 2023 Earnings Presentation
5 slides from Danaher's earnings presentation, Jan 8, 2024
Slide 1: Forward Looking Statements
1 Forward Looking Statements Statements in this presentation that are not strictly historical, including any statements regarding Danaher’s anticipated financial performance and any other statements regarding events or developments that we believe or anticipate will or may occur in the future are "f
Slide 2: Estimated Change Three-Month Period Ended December 31, 2023
ba DANAHER CORPORATION ‘% Estimated Change Throe-Month Period Ended Decembor 31, 2023 ‘vs. Comparable 2022 Period Total sales decline (GAAP) -Low-double digit Impact of: Acquisitions/divestitures Essentially flat Currency exchange rates ow-single digit Core sales decline (non-GAAP) -Low-double digit
Slide 3: Current Update
3 Current Update Better-than-anticipated Q4 results in a challenging operating environment Better-than-anticipated Q4 2023 revenue • Base business core revenue declined mid-single digits • Life Sciences and Biotechnology both modestly above expectations • Respiratory revenue of >$600M at Cepheid exc
Slide 4: Portfolio Transformation Into a Stronger, Better Danaher
4 Dx EAS D ental LS Portfolio Transformation Into a Stronger, Better Danaher Financial profile has improved significantly vs. pre-pandemic 2018 Dx BT LS Total Revenue ~$24B 2023E Portfolio Exits Total Revenue ~$20B ~$2.8B Dental revenue at 2019 IPO ~$4.8B EAS revenue at 2023 spin MSD ~56% ~21% ~$4B
Slide 5: Leading positions in attractive, fast-growing end markets
5 Enhanced with innovation & DBS to accelerate growth & earnings Leading positions in attractive, fast-growing end markets • Long-term, strong secular growth drivers • Regulatory requirements High-Quality Businesses in Attractive End Markets Pie charts are a % of 2023E total revenue from continuing